Neurotech was a previous investment and under our team’s management in the past. It is a prime example of how Israeli impact companies evolve and are eventually able to go mainstream.
Neurotech offers an online, real-time evaluation tool for people with ADHD. While the software company focuses on ADHD, its technology is intended for use as a wider infrastructure to further develop products targeted at a variety of cognitive functions. Neurotech brings a new and advanced algorithm to the forefront, complete with a user-friendly interface, equipped with precision and acuity for home-users and clinicians. The chief goal is to improve the understanding of the vast spectrum of human attention and behavior, permitting medical professionals to elevate patients’ quotidian functioning, overall well-being, and academic performance and achievement.
NeuroTech Solutions has designed The MOXO Home Edition ADHD test for home users and the MOXO clinical tool for clinicians. The home edition allows the home user to assess his/her cognitive abilities by asking him/her to perform various computerized tasks that require continuous attention and reaction. This test offers the most accurate self- profiling ADHD assessment tool available on the market as it covers all four of ADHD’s core elements: inattentiveness, hyperactivity, impulsivity, and timing. The results of the home- based test allow the home user to better understand his/her condition and alert him/her to the need for a more definitive and comprehensive assessment.
The MOXO internet-based ADHD clinical tool employs a new and innovative algorithm that includes visual and auditory distracters that elicits a more thorough understanding of the specific features underlying each patient’s ADHD condition. The MOXO examines and identifies the patient’s Attention performance separately from any Hyperactivity responses and tendencies to Impulsiveness. Furthermore, the MOXO supplies an additional Timing component, which refers to the reaction time of correct responses. Using these four measures, the MOXO creates a specific profile of the difficulties and strengths for each patient, allowing for an accurate, comprehensive, specifically tailored evaluation. The tool achieves 95% accuracy compared to less than 70% when using the traditional “gold standard”. After the conclusion of the test, the personalized data summary is presented in an easy to read graphical display, and each ADHD case is properly subcategorized.
ADHD is the most commonly studied and diagnosed psychiatric disorder in children. It is such a prevalent disorder that UNICEF deemed it “a world epidemic”. Extensive research concludes that untreated ADHD may directly correlate to antisocial conduct, substance abuse, delinquency, and tendency towards criminal/violent behavior. This is true because many people who suffer from ADHD have difficulty analyzing and anticipating consequences as well as learning from their past behavior. It is estimated that at least 25% of prisoners in the US have ADHD. Although approximately 5% – 15% of the world population suffers from ADHD, currently, only 2.5% of sufferers are diagnosed. Diagnosis is challenging due to a number of factors. Perhaps the most apparent is that ADHD is a comorbid disorder, existing alone in only about 1/3 of those diagnosed. Its symptoms can be difficult to differentiate from other disorders such as: Conduct Disorder, Antisocial Personality Disorder, Borderline Personality Disorder, Anxiety Disorder, Depression, etc. By conducting highly accurate ADHD evaluation tests on a much wider scale, sufferers of ADHD, their families, and medical professionals will be better equipped to handle the challenges surrounding diagnosis and implement more advanced and highly specialized treatments.